GlucoTrack（GCTK）株式概要医療機器メーカーであるグルコトラック社は、米国で糖尿病患者向けの埋め込み型持続血糖モニター（CBGM）の開発に注力している。 詳細GCTK ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析キャッシュランウェイが1年未満である US市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( $2M )+2 さらなるリスクすべてのリスクチェックを見るGCTK Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.80該当なし内在価値ディスカウントEst. Revenue$PastFuture-40m612k2016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesGlucoTrack, Inc. 競合他社ENvue MedicalSymbol: NasdaqCM:FEEDMarket cap: US$1.3mEscalon MedicalSymbol: OTCPK:ESMCMarket cap: US$1.3mBluejay DiagnosticsSymbol: NasdaqCM:BJDXMarket cap: US$2.0mSonendoSymbol: OTCPK:SONXMarket cap: US$2.4m価格と性能株価の高値、安値、推移の概要GlucoTrack過去の株価現在の株価US$0.8052週高値US$15.9052週安値US$0.62ベータ0.611ヶ月の変化-6.98%3ヶ月変化-59.18%1年変化-92.10%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースGlucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring TechnologyApr 23High number of new and inexperienced directors Apr 04New major risk - Financial position Apr 01Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 MilestonesMar 27New major risk - Share price stability Feb 01GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.999997 million.Dec 30最新情報をもっと見るRecent updatesGlucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring TechnologyApr 23High number of new and inexperienced directors Apr 04New major risk - Financial position Apr 01Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 MilestonesMar 27New major risk - Share price stability Feb 01GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.999997 million.Dec 30New major risk - Financial position Nov 16Glucotrack, Inc. Appoints Usman Latif to its Clinical Advisory TeamOct 30GlucoTrack, Inc. announced that it has received $3 million in fundingSep 13GlucoTrack, Inc. announced that it expects to receive $20 million in funding from Sixth Borough Capital Management, LP.Sep 12Glucotrack, Inc. Appoints David S. Hirsh, MD as Medical Director, CardiologyAug 06Glucotrack, Inc. and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor At American Diabetes Association's 85Th Scientific SessionsJun 25Glucotrack, Inc. Approves the Election of Victoria Carr-Brendel as DirectorMay 24New major risk - Financial position May 15Glucotrack, Inc. Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose MonitorMay 14GlucoTrack, Inc., Annual General Meeting, May 22, 2025Apr 22Nasdaq Determines to Delist GlucoTrack Securities Due to Non-Compliance with Bid Price RuleApr 05Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board MemberFeb 26GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.033748 million.Feb 05Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose MonitorFeb 04GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price RequirementJan 31GlucoTrack, Inc. Announces Chief Financial Officer ChangesJan 30GlucoTrack, Inc. Receives Nasdaq Non-Compliance Letter Regarding Bid Price RuleJan 01GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $8.23 million.Dec 18GlucoTrack, Inc. Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose MonitorDec 03GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million.Nov 15Glucotrack, Inc. Appoints John Ballantyne to Its Board of DirectorsSep 03GlucoTrack, Inc. announced that it has received $0.1 million in fundingJul 02Glucotrack Announces the Appointment of Andy Balo to Board of DirectorsJun 20Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring SensorJun 15Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose MonitorJun 06GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance PeriodMay 25Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical StudyMay 18Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price RequirementMay 17GlucoTrack, Inc. announced that it has received $0.5 million in fundingApr 23GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose MonitoringApr 18Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose MonitorApr 03GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024Apr 02Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of DirectorsFeb 13GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose MonitorJan 03GlucoTrack, Inc. Announces Executive ChangesOct 13Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit CommitteeSep 01Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose MonitorJul 26GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)Jun 03Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain ComplianceFeb 14Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring SystemOct 11GlucoTrack to start R&D program for glucose monitoring system Oct 10GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose MonitorJun 23Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022Mar 29Integrity Applications, Inc. announced delayed 10-Q filingMay 18Integrity Applications, Inc. announced delayed annual 10-K filingApr 02Integrity Applications, Inc. Announces Executive ChangesFeb 10Integrity Applications Appoints Paul V. Goode to Board of DirectorsDec 19Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020Nov 06Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020Oct 10株主還元GCTKUS Medical EquipmentUS 市場7D9.1%-4.2%0.8%1Y-92.1%-18.5%27.8%株主還元を見る業界別リターン: GCTK過去 1 年間で-18.5 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: GCTKは、過去 1 年間で27.8 % のリターンを上げたUS市場を下回りました。価格変動Is GCTK's price volatile compared to industry and market?GCTK volatilityGCTK Average Weekly Movement18.9%Medical Equipment Industry Average Movement8.2%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: GCTKの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: GCTKの 週次ボラティリティ は過去 1 年間で25%から19%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200111Paul Goodeglucotrack.com医療機器メーカーであるグルコトラック社は、米国で糖尿病患者向けの埋め込み型持続血糖モニター（CBGM）の開発に注力している。同社は、1型糖尿病患者およびインスリン依存の2型糖尿病患者が使用する長期植え込み型血液ベースCBGMであるグルコトラックCBGMを開発している。同社は以前はIntegrity Applications, Inc.として知られていたが、2021年11月にGlucoTrack, Inc.に社名を変更した。グルコトラック社は2001年に設立され、ニュージャージー州ラザフォードに本社を置いている。もっと見るGlucoTrack, Inc. 基礎のまとめGlucoTrack の収益と売上を時価総額と比較するとどうか。GCTK 基礎統計学時価総額US$1.56m収益（TTM）-US$19.39m売上高(TTM)n/a0.0xP/Sレシオ-0.1xPER（株価収益率GCTK は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GCTK 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$19.39m収益-US$19.39m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-9.97グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率120.7%GCTK の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 01:03終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GlucoTrack, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Glucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring TechnologyApr 23
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 MilestonesMar 27
Glucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring TechnologyApr 23
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 MilestonesMar 27
GlucoTrack, Inc. announced that it expects to receive $20 million in funding from Sixth Borough Capital Management, LP.Sep 12
Glucotrack, Inc. and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor At American Diabetes Association's 85Th Scientific SessionsJun 25
Glucotrack, Inc. Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose MonitorMay 14
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board MemberFeb 26
Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose MonitorFeb 04
GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price RequirementJan 31
GlucoTrack, Inc. Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose MonitorDec 03
Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring SensorJun 15
Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose MonitorJun 06
GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance PeriodMay 25
Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical StudyMay 18
Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price RequirementMay 17
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose MonitoringApr 18
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose MonitorApr 03
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit CommitteeSep 01
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose MonitorJul 26
GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)Jun 03
Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain ComplianceFeb 14
Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022Mar 29
Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020Nov 06
Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020Oct 10
